Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with complex heritability and higher prevalence in males. Since the neonatal epigenome has the potential to reflect past interactions between genetic and environmental factors during early development, we performed whole-genome bisulfite sequencing of 152 umbilical cord blood samples from the MARBLES and EARLI high-familial risk prospective cohorts to identify an epigenomic signature of ASD at birth.
Results:We identified differentially-methylated regions (DMRs) stratified by sex that discriminated ASD from control cord blood samples in discovery and replication sets. At a region level, 7 DMRs in males and 31 DMRs in females replicated across two independent groups of subjects, while 537 DMR genes in males and 1762 DMR genes in females replicated by gene association. These DMR genes were significantly enriched for brain and embryonic expression, X chromosome location, and identification in prior epigenetic studies of ASD in postmortem brain. In males and females, autosomal ASD DMRs were significantly enriched for promoter and bivalent chromatin states across most cell types, while sex differences were observed for X-linked ASD DMRs. Lastly, these DMRs identified in cord blood were significantly enriched for binding sites of methyl-sensitive transcription factors relevant to fetal brain 3 development.
Conclusions:At birth, prior to the diagnosis of ASD, a distinct DNA methylation signature was detected in cord blood over regulatory regions and genes relevant to early fetal neurodevelopment. Differential cord methylation in ASD supports the developmental and sexbiased etiology of ASD, and provides novel insights for early diagnosis and therapy.
Keywordsautism spectrum disorder, neurodevelopment, umbilical cord blood, prospective study, epigenome wide association study, epigenetics, epigenome, DNA methylation, whole genome bisulfite sequencing, x chromosome Background Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder that affects 1 in 59 children in the United States [1]. ASD presents as persistent difficulties in social communication and interaction, restricted and repetitive behaviors and interests, as well as sensory sensitivities. Communication deficits can include delayed and monotonous speech, echolalia, poor verbal comprehension, difficulty understanding body language cues, and making eye contact, while behavioral deficits can include stereotyped movements, insistence on routine, fixated interests, and altered sensitivity to sensory input. ASD is currently diagnosed in childhood by one of several standardized scales that include interviews, behavioral observation, and clinical assessment, such as the gold standard Autism Diagnostic Observation Schedule (ADOS) [2,3]. Clinical management of ASD symptoms consists of both behavioral interventions and pharmacological treatments. Intensive behavioral interventions have been associated with better outcomes in children with ASD, especially for those diagnosed withi...